Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1972 2
1974 1
1976 1
1980 1
1982 1
1983 1
1984 1
1985 3
1986 3
1987 63
1988 171
1989 161
1990 147
1991 155
1992 167
1993 181
1994 231
1995 197
1996 214
1997 220
1998 272
1999 321
2000 319
2001 348
2002 411
2003 412
2004 476
2005 484
2006 555
2007 559
2008 616
2009 611
2010 632
2011 668
2012 693
2013 834
2014 1212
2015 1470
2016 1552
2017 1653
2018 1719
2019 1793
2020 1979
2021 1537
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

20,592 results
Results by year
Filters applied: . Clear all
Page 1
Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM. Ansell SM. Mayo Clin Proc. 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. Mayo Clin Proc. 2015. PMID: 26541251 Review.
Patients with early-stage Hodgkin lymphoma commonly receive combined-modality therapies that include abbreviated courses of chemotherapy followed by involved-field radiation treatment. In contrast, patients with advanced-stage Hodgkin lymphoma commonly receive a more prolo …
Patients with early-stage Hodgkin lymphoma commonly receive combined-modality therapies that include abbreviated courses of chemotherapy
Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Kelley RK, et al. J Hepatol. 2020 Feb;72(2):353-363. doi: 10.1016/j.jhep.2019.10.009. J Hepatol. 2020. PMID: 31954497 Review.
The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic chemotherapy. Compared to hepatocellular carcinoma, iCCA is genetically distinct with several targetable genetic aberrations identifi …
The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic …
Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D, Mandrekar SJ, Wigle D, Roden AC, Adjei AA. Uprety D, et al. J Thorac Oncol. 2020 Aug;15(8):1281-1297. doi: 10.1016/j.jtho.2020.05.020. Epub 2020 Jun 6. J Thorac Oncol. 2020. PMID: 32522713 Free article.
Patients with resectable NSCLC are often treated with surgery and adjuvant chemotherapy. However, these patients continue to have a high risk of recurrence and death. ...A systematic review of 32 randomized trials involving 10,000 patients revealed that there was no differ …
Patients with resectable NSCLC are often treated with surgery and adjuvant chemotherapy. However, these patients continue to have a h …
Extracellular vesicle-based drug delivery systems for cancer treatment.
Walker S, Busatto S, Pham A, Tian M, Suh A, Carson K, Quintero A, Lafrence M, Malik H, Santana MX, Wolfram J. Walker S, et al. Theranostics. 2019 Oct 17;9(26):8001-8017. doi: 10.7150/thno.37097. eCollection 2019. Theranostics. 2019. PMID: 31754377 Free PMC article. Review.
EVs have also been found to display tissue tropism mediated by surface molecules, such as integrins and glycans, making them promising for drug delivery applications. Various methods can be used to load therapeutic agents into EVs, and additional modification strategies ha …
EVs have also been found to display tissue tropism mediated by surface molecules, such as integrins and glycans, making them promising for …
First-Line Therapy for Metastatic Soft Tissue Sarcoma.
Meyer M, Seetharam M. Meyer M, et al. Curr Treat Options Oncol. 2019 Jan 24;20(1):6. doi: 10.1007/s11864-019-0606-9. Curr Treat Options Oncol. 2019. PMID: 30675651 Review.
More recently, immunotherapy has been tested in select histotypes of sarcoma with encouraging activity and has led to further evaluation in combination with immunotherapeutic agents, as well as with chemotherapy and radiation treatments. Here, in this article, we summarize …
More recently, immunotherapy has been tested in select histotypes of sarcoma with encouraging activity and has led to further evaluation in …
Second-line therapies in advanced biliary tract cancers.
Tella SH, Kommalapati A, Borad MJ, Mahipal A. Tella SH, et al. Lancet Oncol. 2020 Jan;21(1):e29-e41. doi: 10.1016/S1470-2045(19)30733-8. Lancet Oncol. 2020. PMID: 31908303 Review.
Biliary tract cancers constitute approximately 3% of gastrointestinal malignancies with poor prognosis. Surgical therapy is the main form of treatment in localised disease; however, for patients with advanced stage or unresectable disease, locoregional and systemic chemoth …
Biliary tract cancers constitute approximately 3% of gastrointestinal malignancies with poor prognosis. Surgical therapy is the main …
The timing of breast and axillary surgery after neoadjuvant chemotherapy for breast cancer.
Al-Hilli Z, Boughey JC. Al-Hilli Z, et al. Chin Clin Oncol. 2016 Jun;5(3):37. doi: 10.21037/cco.2016.03.26. Epub 2016 Apr 22. Chin Clin Oncol. 2016. PMID: 27164853 Free article. Review.
Neoadjuvant chemotherapy (NAC) has traditionally been used in locally advanced and inflammatory breast cancer, allowing for a reduction in disease volume and therefore optimizing surgical resection of disease in the breast. ...
Neoadjuvant chemotherapy (NAC) has traditionally been used in locally advanced and inflammatory breast cancer, allowing for a reducti …
Microsatellite instability testing and its role in the management of colorectal cancer.
Kawakami H, Zaanan A, Sinicrope FA. Kawakami H, et al. Curr Treat Options Oncol. 2015 Jul;16(7):30. doi: 10.1007/s11864-015-0348-2. Curr Treat Options Oncol. 2015. PMID: 26031544 Free PMC article. Review.
Available data indicate that patients with stage II dMMR CRCs have an excellent prognosis and do not benefit from 5-fluorouracil (FU)-based adjuvant chemotherapy which supports their recommended management by surgery alone. In contrast, the benefit of standard adjuvant …
Available data indicate that patients with stage II dMMR CRCs have an excellent prognosis and do not benefit from 5-fluorouracil (FU)-based …
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.
Bekaii-Saab T, Kim R, Kim TW, O'Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, Yoshino T, Prager GW. Bekaii-Saab T, et al. Clin Colorectal Cancer. 2019 Mar;18(1):e117-e129. doi: 10.1016/j.clcc.2018.11.002. Epub 2018 Nov 16. Clin Colorectal Cancer. 2019. PMID: 30598357 Free article. Review.
An increasing number of patients with metastatic colorectal cancer (mCRC) are able to receive 3 or more lines of therapy. Treatments in this setting can include regorafenib (an oral multikinase inhibitor), trifluridine/tipiracil hydrochloride (TAS-102), antibodies that tar …
An increasing number of patients with metastatic colorectal cancer (mCRC) are able to receive 3 or more lines of therapy. Treatments …
Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients.
Kasi PM, Grothey A. Kasi PM, et al. Drugs. 2018 May;78(7):737-745. doi: 10.1007/s40265-018-0909-3. Drugs. 2018. PMID: 29754293 Review.
Chemotherapy-induced neutropenia (CIN) is one of the most common side effects seen in cancer patients. ...It is also associated with a financial cost component from diagnostic work-up and treatment of patients with chemotherapy-induced febrile neutropenia (CIFN). Ne
Chemotherapy-induced neutropenia (CIN) is one of the most common side effects seen in cancer patients. ...It is also associated with
20,592 results
You have reached the last available page of results. Please see the User Guide for more information.